Targeting Hb with aromatic aldehydes to prevent deoxygenation-induced HbS polymerization and RBC sickling has long been considered the gold standard for targeting Hb for SCD therapeutics [4,15]. The gene discussed is GSTM1; the disease is Schnyder corneal dystrophy.